IGMS News and Press, IGM Biosciences Inc. From 08/03/23

2023-08-03 17:41:02 ET IGM Biosciences press release ( NASDAQ: IGMS ): Q2 GAAP EPS of -$1.43 beats by $0.01 . Revenue of $0.45M (+21.6% Y/Y) misses by $0.34M . For further details see: IGM Biosciences GAAP EPS of -$1.43 beats by $0.01, revenue of $0.45M m...

– Continued progress in clinical development across portfolio – – Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS)...

2023-07-16 09:06:49 ET Summary IGM Biosciences, developing IgM antibodies for various diseases, sees Q1 2023 cash decrease, but collaboration revenues rise. Imvotamab trial results disappoint; focus shifts to combination therapies, while IGM-8444, IGM-7354, IGM-2644 show potential...

2023-07-13 08:30:00 ET Summary June 2023 saw significant insider purchases in Lucid Group, Diversified Healthcare Trust, Akoya Biosciences, and Axon Enterprise. The Public Investment Fund bought $1.8 billion worth of shares in Lucid Group, increasing its ownership to 74.95%. Diver...

MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of 1,597,827 shares of its voting common stock and 9,000,000 shares of its non-voting common stock and includi...

2023-06-22 10:02:12 ET Gainers: TRxADE HEALTH ( MEDS ) +39% . Talaris Therapeutics ( TALS ) +25% . IGM Biosciences ( IGMS ) +11% . Predictive Oncology ( POAI ) +4% . Zymeworks ( ZYME ) +3% . Losers: Innovative Eyewear...

2023-06-22 08:28:06 ET IGM Biosciences ( NASDAQ: IGMS ) has announced the pricing of its upsized underwritten public offering of 3.29M shares of its voting common stock and 7.31M shares of its non-voting common stock, in each case at a price to the public of $8/share. ...

MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and 7,312,500 shares of its non-voting common stock, in each case at a price to the ...

2023-06-21 17:35:02 ET IGM Biosciences ( NASDAQ: IGMS ) said Wednesday that it intends to offer and sell $100 million of its common stock in an underwritten public offering. Underwriters have a 30-day option to purchase up to an additional 15% of the shares being offered...

MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, i...